Literature DB >> 31727504

Immunogenicity of the Lyme disease antigen OspA, particleized by cobalt porphyrin-phospholipid liposomes.

Jasmin Federizon1, Amber Frye2, Wei-Chiao Huang1, Thomas M Hart3, Xuedan He1, Christopher Beltran4, Ashley L Marcinkiewicz4, Iain L Mainprize5, Melanie K B Wills5, Yi-Pin Lin2, Jonathan F Lovell6.   

Abstract

Outer surface protein A (OspA) is a Borrelia lipoprotein and an established Lyme disease vaccine target. Admixing non-lipidated, recombinant B. burgdorferi OspA with liposomes containing cobalt porphyrin-phospholipid (CoPoP) resulted in rapid, particulate surface display of the conformationally intact antigen. Particleization was serum-stable and led to enhanced antigen uptake in murine macrophages in vitro. Mouse immunization using CoPoP liposomes that also contained a synthetic monophosphoryl lipid A (PHAD) elicited a Th1-biased OspA antibody response with higher IgG production compared to other vaccine adjuvants. Antibodies were reactive with intact B. burgdorferi spirochetes and Borrelia lysates, and induced complement-mediated borreliacidal activity in vitro. One year after initial immunization, mice maintained high levels of circulating borreliacidal antibodies capable of blocking B. burgdorferi transmission from infected ticks to human blood in a feeding chamber.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Adjuvant; Liposomes; Lyme disease; OspA; Particle vaccine

Year:  2019        PMID: 31727504      PMCID: PMC6980772          DOI: 10.1016/j.vaccine.2019.10.073

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  45 in total

1.  Blood treatment of Lyme borreliae demonstrates the mechanism of CspZ-mediated complement evasion to promote systemic infection in vertebrate hosts.

Authors:  Ashley L Marcinkiewicz; Alan P Dupuis; Maxime Zamba-Campero; Nancy Nowak; Peter Kraiczy; Sanjay Ram; Laura D Kramer; Yi-Pin Lin
Journal:  Cell Microbiol       Date:  2019-01-07       Impact factor: 3.715

Review 2.  Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens.

Authors:  Yvonne Perrie; Afzal R Mohammed; Daniel J Kirby; Sarah E McNeil; Vincent W Bramwell
Journal:  Int J Pharm       Date:  2008-04-30       Impact factor: 5.875

3.  The spirochetal etiology of Lyme disease.

Authors:  A C Steere; R L Grodzicki; A N Kornblatt; J E Craft; A G Barbour; W Burgdorfer; G P Schmid; E Johnson; S E Malawista
Journal:  N Engl J Med       Date:  1983-03-31       Impact factor: 91.245

4.  Structural analysis of an outer surface protein from the Lyme disease spirochete, Borrelia burgdorferi, using circular dichroism and fluorescence spectroscopy.

Authors:  L L France; J Kieleczawa; J J Dunn; G Hind; J C Sutherland
Journal:  Biochim Biophys Acta       Date:  1992-03-27

5.  Use of a C6 ELISA test to evaluate the efficacy of a whole-cell bacterin for the prevention of naturally transmitted canine Borrelia burgdorferi infection.

Authors:  Steven A Levy
Journal:  Vet Ther       Date:  2002

6.  Outer surface protein A (OspA) from the Lyme disease spirochete, Borrelia burgdorferi: high level expression and purification of a soluble recombinant form of OspA.

Authors:  J J Dunn; B N Lade; A G Barbour
Journal:  Protein Expr Purif       Date:  1990-11       Impact factor: 1.650

7.  Elimination of Borrelia burgdorferi from vector ticks feeding on OspA-immunized mice.

Authors:  E Fikrig; S R Telford; S W Barthold; F S Kantor; A Spielman; R A Flavell
Journal:  Proc Natl Acad Sci U S A       Date:  1992-06-15       Impact factor: 11.205

8.  Biological activities of native and recombinant Borrelia burgdorferi outer surface protein A: dependence on lipid modification.

Authors:  J J Weis; Y Ma; L F Erdile
Journal:  Infect Immun       Date:  1994-10       Impact factor: 3.441

9.  Functionalization of cobalt porphyrin-phospholipid bilayers with his-tagged ligands and antigens.

Authors:  Shuai Shao; Jumin Geng; Hyun Ah Yi; Shobhit Gogia; Sriram Neelamegham; Amy Jacobs; Jonathan F Lovell
Journal:  Nat Chem       Date:  2015-04-20       Impact factor: 24.427

10.  The novel Lyme borreliosis vaccine VLA15 shows broad protection against Borrelia species expressing six different OspA serotypes.

Authors:  Pär Comstedt; Wolfgang Schüler; Andreas Meinke; Urban Lundberg
Journal:  PLoS One       Date:  2017-09-01       Impact factor: 3.240

View more
  12 in total

Review 1.  Past, present, and future of Lyme disease vaccines: antigen engineering approaches and mechanistic insights.

Authors:  Wen-Hsiang Chen; Ulrich Strych; Maria Elena Bottazzi; Yi-Pin Lin
Journal:  Expert Rev Vaccines       Date:  2022-07-22       Impact factor: 5.683

2.  Agglutination of Borreliella burgdorferi by Transmission-Blocking OspA Monoclonal Antibodies and Monovalent Fab Fragments.

Authors:  Amber M Frye; Monir Ejemel; Lisa Cavacini; Yang Wang; Michael J Rudolph; Renjie Song; Nicholas J Mantis
Journal:  Infect Immun       Date:  2022-08-24       Impact factor: 3.609

3.  Respiratory Vaccination with Hemagglutinin Nanoliposomes Protects Mice from Homologous and Heterologous Strains of Influenza Virus.

Authors:  Zachary R Sia; Kevin Chiem; Wei-Chiao Huang; Amal Seffouh; Amir Teimouri Dereshgi; Tara Hogan; Joaquin Ortega; Bruce A Davidson; Luis Martinez-Sobrido; Jonathan F Lovell
Journal:  J Virol       Date:  2022-09-15       Impact factor: 6.549

4.  An In Vivo Screen to Identify Short Peptide Mimotopes with Enhanced Antitumor Immunogenicity.

Authors:  Xuedan He; Shiqi Zhou; Breandan Quinn; Dushyant Jahagirdar; Joaquin Ortega; Mark D Long; Scott I Abrams; Jonathan F Lovell
Journal:  Cancer Immunol Res       Date:  2022-03-01       Impact factor: 12.020

5.  Lyophilized, antigen-bound liposomes with reduced MPLA and enhanced thermostability.

Authors:  Moustafa T Mabrouk; Wei-Chiao Huang; Bingbing Deng; Nasi Li-Purcell; Amal Seffouh; Joaquin Ortega; Gunes Ekin Atilla-Gokcumen; Carole A Long; Kazutoyo Miura; Jonathan F Lovell
Journal:  Int J Pharm       Date:  2020-09-02       Impact factor: 5.875

6.  HPV-Associated Tumor Eradication by Vaccination with Synthetic Short Peptides and Particle-Forming Liposomes.

Authors:  Xuedan He; Shiqi Zhou; Breandan Quinn; Dushyant Jahagirdar; Joaquin Ortega; Scott I Abrams; Jonathan F Lovell
Journal:  Small       Date:  2021-02-19       Impact factor: 13.281

7.  A liposome-displayed hemagglutinin vaccine platform protects mice and ferrets from heterologous influenza virus challenge.

Authors:  Zachary R Sia; Xuedan He; Ali Zhang; Jann C Ang; Shuai Shao; Amal Seffouh; Wei-Chiao Huang; Michael R D'Agostino; Amir Teimouri Dereshgi; Sambhara Suryaprakash; Joaquin Ortega; Hanne Andersen; Matthew S Miller; Bruce A Davidson; Jonathan F Lovell
Journal:  Proc Natl Acad Sci U S A       Date:  2021-06-01       Impact factor: 11.205

8.  Experimental and Computational Observations of Immunogenic Cobalt Porphyrin Lipid Bilayers: Nanodomain-Enhanced Antigen Association.

Authors:  Jasmin Federizon; Conrard Giresse Tetsassi Feugmo; Wei-Chiao Huang; Xuedan He; Kazutoyo Miura; Aida Razi; Joaquin Ortega; Mikko Karttunen; Jonathan F Lovell
Journal:  Pharmaceutics       Date:  2021-01-14       Impact factor: 6.321

9.  Antibody response of a particle-inducing, liposome vaccine adjuvant admixed with a Pfs230 fragment.

Authors:  Wei-Chiao Huang; Bingbing Deng; Amal Seffouh; Joaquin Ortega; Carole A Long; Ragavan V Suresh; Xuedan He; Kazutoyo Miura; Shwu-Maan Lee; Yimin Wu; Jonathan F Lovell
Journal:  NPJ Vaccines       Date:  2020-03-18       Impact factor: 7.344

10.  SARS-CoV-2 RBD Neutralizing Antibody Induction is Enhanced by Particulate Vaccination.

Authors:  Wei-Chiao Huang; Shiqi Zhou; Xuedan He; Kevin Chiem; Moustafa T Mabrouk; Ruth H Nissly; Ian M Bird; Mike Strauss; Suryaprakash Sambhara; Joaquin Ortega; Elizabeth A Wohlfert; Luis Martinez-Sobrido; Suresh V Kuchipudi; Bruce A Davidson; Jonathan F Lovell
Journal:  Adv Mater       Date:  2020-10-28       Impact factor: 32.086

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.